TAKEDA PHARMACEUTICAL COMPANY LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4,285 JPY | -0.56% |
|
-0.63% | +5.70% |
| Jul. 17 | Asian Equities Traded in the US as American Depositary Receipts Tumble in Wednesday Trading | MT |
| Jul. 17 | Zydus Lifesciences Signs Licensing Pact to Market Vonoprazan in India | MT |
Takeda Pharmaceutical Company Limited specializes in the development, manufacturing and marketing of pharmaceutical products especially for metabolic and cardiovascular diseases, cancers and central nervous systems troubles. The activity is organized around 2 areas:
- sale of drugs and consumer care products;
- services.
Net sales are distributed geographically as follows: Japan (17.5%), Asia (5%), the United States (49%), Europe and Canada (20.8%), Latin America (3.8%), Russia and CIS (1.8%) and other (2.1%).
Sector
Pharmaceuticals
Calendar
2024-07-31
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
4,309
JPY
Average target price
4,730
JPY
Spread / Average Target
+9.77%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +5.70% | 43.61B | |
| +55.35% | 815B | |
| +32.37% | 597B | |
| -0.10% | 377B | |
| +15.47% | 319B | |
| +13.10% | 310B | |
| +16.34% | 247B | |
| +15.13% | 228B | |
| +16.54% | 180B | |
| +4.31% | 170B |
- Stock Market
- Equities
- 4502 Stock
- News Takeda Pharmaceutical Company Limited
- WHO prequalifies new dengue vaccine
